Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry A J Struijker-Boudier

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Hypertension (Dallas, Tex. : 1979)|February 13, 2008
Retinal microcirculation and early mechanisms of hypertensionHarry A J Struijker-Boudier
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|August 22, 2003
The right drug and the right doseHarry A J Struijker-Boudier
Drugs|April 24, 2003
[New goals in hypertension management: target-organ protection beyond blood pressure lowering]Michel E Safar, Harry A J Struijker-Boudier
Hypertension (Dallas, Tex. : 1979)|October 5, 2011
Early life microcirculation and the development of hypertensionHarry A J Struijker-Boudier, Bart F J Heijnen
Trends in Pharmacological Sciences|April 5, 2002
Problem-based learning: the Maastricht experienceHarry A J Struijker Boudier, Jos F M Smits
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|August 22, 2003
The heart, macrocirculation and microcirculation in hypertension: a unifying hypothesisHarry A J Struijker Boudier, Géraldine M S Cohuet, Marcus Baumann, et al.
Hypertension (Dallas, Tex. : 1979)|June 27, 2012
Phenotyping the microcirculationHarry A J Struijker-Boudier, Bart F J Heijnen, Yan-Ping Liu, et al.
Hypertension (Dallas, Tex. : 1979)|February 7, 2023
VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?Ferdinand A C le Noble, Jean-Jacques Mourad, Bernard I Levy, et al.
American Journal of Hypertension|January 12, 2008
Sustained tubulo-interstitial protection in SHRs by transient losartan treatment: an effect of decelerated aging?Marcus Baumann, Roger Bartholome, Carine J Peutz-Kootstra, et al.
Plos One|October 28, 2015
Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot StudyRaffaele Altara, Yu-Mei Gu, Harry A J Struijker-Boudier, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Hypertension (Dallas, Tex. : 1979)|February 13, 2008
Retinal microcirculation and early mechanisms of hypertensionHarry A J Struijker-Boudier
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|August 22, 2003
The right drug and the right doseHarry A J Struijker-Boudier
Drugs|April 24, 2003
[New goals in hypertension management: target-organ protection beyond blood pressure lowering]Michel E Safar, Harry A J Struijker-Boudier
Hypertension (Dallas, Tex. : 1979)|October 5, 2011
Early life microcirculation and the development of hypertensionHarry A J Struijker-Boudier, Bart F J Heijnen
Trends in Pharmacological Sciences|April 5, 2002
Problem-based learning: the Maastricht experienceHarry A J Struijker Boudier, Jos F M Smits
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|August 22, 2003
The heart, macrocirculation and microcirculation in hypertension: a unifying hypothesisHarry A J Struijker Boudier, Géraldine M S Cohuet, Marcus Baumann, et al.
Hypertension (Dallas, Tex. : 1979)|June 27, 2012
Phenotyping the microcirculationHarry A J Struijker-Boudier, Bart F J Heijnen, Yan-Ping Liu, et al.
Hypertension (Dallas, Tex. : 1979)|February 7, 2023
VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?Ferdinand A C le Noble, Jean-Jacques Mourad, Bernard I Levy, et al.
American Journal of Hypertension|January 12, 2008
Sustained tubulo-interstitial protection in SHRs by transient losartan treatment: an effect of decelerated aging?Marcus Baumann, Roger Bartholome, Carine J Peutz-Kootstra, et al.
Plos One|October 28, 2015
Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot StudyRaffaele Altara, Yu-Mei Gu, Harry A J Struijker-Boudier, et al.
Pageof 6